Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan

72Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole, and voriconazole were above the ECV were 7.1%, 2.6%, and 4.1%, respectively. A G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) and 100% (5/5 isolates) of non-WT isolates for itraconazole and posaconazole, respectively. Amphotericin B MICs of ≥2 μg/ml and micafungin minimum effective concentrations (MECs) of ≥16 μg/ml were recorded for two and one isolates, respectively. Copyright © 2012, American Society for Microbiology. All Rights Reserved.

Cite

CITATION STYLE

APA

Tashiro, M., Izumikawa, K., Minematsu, A., Hirano, K., Iwanaga, N., Ide, S., … Kohno, S. (2012). Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrobial Agents and Chemotherapy, 56(1), 584–587. https://doi.org/10.1128/AAC.05394-11

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free